212 related articles for article (PubMed ID: 36923556)
1. TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies.
Carideo Cunniff E; Sato Y; Mai D; Appleman VA; Iwasaki S; Kolev V; Matsuda A; Shi J; Mochizuki M; Yoshikawa M; Huang J; Shen L; Haridas S; Shinde V; Gemski C; Roberts ER; Ghasemi O; Bazzazi H; Menon S; Traore T; Shi P; Thelen TD; Conlon J; Abu-Yousif AO; Arendt C; Shaw MH; Okaniwa M
Cancer Res Commun; 2022 Jun; 2(6):489-502. PubMed ID: 36923556
[TBL] [Abstract][Full Text] [Related]
2. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
[TBL] [Abstract][Full Text] [Related]
3. STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer.
Vonderhaar EP; Barnekow NS; McAllister D; McOlash L; Eid MA; Riese MJ; Tarakanova VL; Johnson BD; Dwinell MB
Cell Mol Gastroenterol Hepatol; 2021; 12(1):41-58. PubMed ID: 33548597
[TBL] [Abstract][Full Text] [Related]
4. STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors.
Perera SA; Kopinja JE; Ma Y; Muise ES; Laskey J; Chakravarthy K; Chen Y; Cui L; Presland J; Sathe M; Javaid S; Minnihan EC; Ferguson HM; Piesvaux J; Pan BS; Zhao S; Sharma SK; Woo HC; Pucci V; Knemeyer I; Cemerski S; Cumming J; Trotter BW; Tse A; Khilnani A; Ranganath S; Long BJ; Bennett DJ; Addona GH
Mol Cancer Ther; 2022 Feb; 21(2):282-293. PubMed ID: 34815361
[TBL] [Abstract][Full Text] [Related]
5. Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity.
Lemos H; Ou R; McCardle C; Lin Y; Calver J; Minett J; Chadli A; Huang L; Mellor AL
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32847988
[TBL] [Abstract][Full Text] [Related]
6. TREX1 Inactivation Unleashes Cancer Cell STING-Interferon Signaling and Promotes Antitumor Immunity.
Tani T; Mathsyaraja H; Campisi M; Li ZH; Haratani K; Fahey CG; Ota K; Mahadevan NR; Shi Y; Saito S; Mizuno K; Thai TC; Sasaki N; Homme M; Yusuf CFB; Kashishian A; Panchal J; Wang M; Wolf BJ; Barbie TU; Paweletz CP; Gokhale PC; Liu D; Uppaluri R; Kitajima S; Cain J; Barbie DA
Cancer Discov; 2024 May; 14(5):752-765. PubMed ID: 38227896
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a Novel Compound That Stimulates STING-Mediated Innate Immune Activity in an Allele-Specific Manner.
Abraham J; Botto S; Mizuno N; Pryke K; Gall B; Boehm D; Sali TM; Jin H; Nilsen A; Gough M; Baird J; Chakhtoura M; Subra C; Trautmann L; Haddad EK; DeFilippis VR
Front Immunol; 2020; 11():1430. PubMed ID: 32733475
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non-Muscle Invasive Murine Bladder Cancer.
Huang KC; Chanda D; McGrath S; Dixit V; Zhang C; Wu J; Tendyke K; Yao H; Hukkanen R; Taylor N; Verbel D; Kim DS; Endo A; Noland TA; Chen Y; Matijevic M; Wang J; Hutz J; Sarwar N; Fang FG; Bao X
Mol Cancer Ther; 2022 Jun; 21(6):914-924. PubMed ID: 35313332
[TBL] [Abstract][Full Text] [Related]
9. Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model.
Kumar S; Schoonderwoerd MJA; Kroonen JS; de Graaf IJ; Sluijter M; Ruano D; González-Prieto R; Verlaan-de Vries M; Rip J; Arens R; de Miranda NFCC; Hawinkels LJAC; van Hall T; Vertegaal ACO
Gut; 2022 Nov; 71(11):2266-2283. PubMed ID: 35074907
[TBL] [Abstract][Full Text] [Related]
10. STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models.
Berger G; Knelson EH; Jimenez-Macias JL; Nowicki MO; Han S; Panagioti E; Lizotte PH; Adu-Berchie K; Stafford A; Dimitrakakis N; Zhou L; Chiocca EA; Mooney DJ; Barbie DA; Lawler SE
Proc Natl Acad Sci U S A; 2022 Jul; 119(28):e2111003119. PubMed ID: 35787058
[TBL] [Abstract][Full Text] [Related]
11. Chemical Biology Perspectives on STING Agonists as Tumor Immunotherapy.
Xuan C; Hu R
ChemMedChem; 2023 Dec; 18(23):e202300405. PubMed ID: 37794702
[TBL] [Abstract][Full Text] [Related]
12. The host STING pathway at the interface of cancer and immunity.
Corrales L; McWhirter SM; Dubensky TW; Gajewski TF
J Clin Invest; 2016 Jul; 126(7):2404-11. PubMed ID: 27367184
[TBL] [Abstract][Full Text] [Related]
13. Targeting STING to promote antitumor immunity.
Chin EN; Sulpizio A; Lairson LL
Trends Cell Biol; 2023 Mar; 33(3):189-203. PubMed ID: 35931610
[TBL] [Abstract][Full Text] [Related]
14. Novel chemical compound SINCRO with dual function in STING-type I interferon and tumor cell death pathways.
Kimura Y; Negishi H; Matsuda A; Endo N; Hangai S; Inoue A; Nishio J; Taniguchi T; Yanai H
Cancer Sci; 2018 Sep; 109(9):2687-2696. PubMed ID: 29981256
[TBL] [Abstract][Full Text] [Related]
15. Discovery and Mechanistic Study of a Novel Human-Stimulator-of-Interferon-Genes Agonist.
Zhang X; Liu B; Tang L; Su Q; Hwang N; Sehgal M; Cheng J; Ma J; Zhang X; Tan Y; Zhou Y; Duan Z; DeFilippis VR; Viswanathan U; Kulp J; Du Y; Guo JT; Chang J
ACS Infect Dis; 2019 Jul; 5(7):1139-1149. PubMed ID: 31060350
[TBL] [Abstract][Full Text] [Related]
16. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer.
Lee SJ; Yang H; Kim WR; Lee YS; Lee WS; Kong SJ; Lee HJ; Kim JH; Cheon J; Kang B; Chon HJ; Kim C
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34145029
[TBL] [Abstract][Full Text] [Related]
17. Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models.
Papaevangelou E; Esteves AM; Dasgupta P; Galustian C
Front Immunol; 2023; 14():1196829. PubMed ID: 37465665
[TBL] [Abstract][Full Text] [Related]
18. Agonist of stimulator of interferon genes as antitumor agents: a patent review (2008-2020).
Chen NN; Zhang H; You QD; Xu XL
Expert Opin Ther Pat; 2021 Jun; 31(6):563-584. PubMed ID: 33459063
[TBL] [Abstract][Full Text] [Related]
19. Targeting STING for cancer immunotherapy: From mechanisms to translation.
Huang R; Ning Q; Zhao J; Zhao X; Zeng L; Yi Y; Tang S
Int Immunopharmacol; 2022 Dec; 113(Pt A):109304. PubMed ID: 36252492
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel amidobenzimidazole derivatives as orally available small molecule modulators of stimulator of interferon genes for cancer immunotherapy.
Jeon MJ; Lee H; Jo S; Kang M; Jeong JH; Jeong SH; Lee JY; Song GY; Choo H; Lee S; Kim H
Eur J Med Chem; 2023 Dec; 261():115834. PubMed ID: 37862818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]